DE69736995D1 - Crystallizable compositions containing a complex of hepatitis C virus protease domain NS3 and NS4A and crystals provided therewith - Google Patents

Crystallizable compositions containing a complex of hepatitis C virus protease domain NS3 and NS4A and crystals provided therewith

Info

Publication number
DE69736995D1
DE69736995D1 DE69736995T DE69736995T DE69736995D1 DE 69736995 D1 DE69736995 D1 DE 69736995D1 DE 69736995 T DE69736995 T DE 69736995T DE 69736995 T DE69736995 T DE 69736995T DE 69736995 D1 DE69736995 D1 DE 69736995D1
Authority
DE
Germany
Prior art keywords
hepatitis
complex
ns4a
virus protease
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736995T
Other languages
German (de)
Other versions
DE69736995T2 (en
Inventor
Joseph L Kim
Kurt A Morgenstern
Chao Lin
Ted Fox
John A Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of DE69736995D1 publication Critical patent/DE69736995D1/en
Application granted granted Critical
Publication of DE69736995T2 publication Critical patent/DE69736995T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Cell Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to compositions and crystals of a hepatitis C virus protease in complex with its viral cofactor. This invention also relates to methods of using the structure coordinates of hepatitis C virus protease in complex with a synthetic NS4A to solve the structure of similar or homologous proteins or protein complexes.
DE69736995T 1996-09-12 1997-09-12 Crystallizable compositions containing a complex of hepatitis C virus protease domain NS3 and NS4A and crystals provided therewith Expired - Lifetime DE69736995T2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US25274P 1996-09-12
US731336 1996-10-18
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex

Publications (2)

Publication Number Publication Date
DE69736995D1 true DE69736995D1 (en) 2007-01-04
DE69736995T2 DE69736995T2 (en) 2007-09-20

Family

ID=26699520

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69736995T Expired - Lifetime DE69736995T2 (en) 1996-09-12 1997-09-12 Crystallizable compositions containing a complex of hepatitis C virus protease domain NS3 and NS4A and crystals provided therewith
DE69723485T Expired - Lifetime DE69723485T2 (en) 1996-09-12 1997-09-12 Method for identifying active substances against HCV using structural coordinates of the hepatitis C virus protease
DE69712085T Expired - Lifetime DE69712085T2 (en) 1996-09-12 1997-09-12 CRYSTALLIZABLE COMPOSITIONS CONTAINING A COMPLEX OF PROTEIN DOMAIN NS3 FROM THE VIRUS OF HEPATITIS C AND NS4A, AND CRYSTALS PROVIDED THEREFORE

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69723485T Expired - Lifetime DE69723485T2 (en) 1996-09-12 1997-09-12 Method for identifying active substances against HCV using structural coordinates of the hepatitis C virus protease
DE69712085T Expired - Lifetime DE69712085T2 (en) 1996-09-12 1997-09-12 CRYSTALLIZABLE COMPOSITIONS CONTAINING A COMPLEX OF PROTEIN DOMAIN NS3 FROM THE VIRUS OF HEPATITIS C AND NS4A, AND CRYSTALS PROVIDED THEREFORE

Country Status (13)

Country Link
US (2) US6153579A (en)
EP (1) EP0935609B1 (en)
JP (1) JP2001501602A (en)
AT (3) ATE346088T1 (en)
AU (1) AU736857B2 (en)
CA (1) CA2264964A1 (en)
DE (3) DE69736995T2 (en)
DK (1) DK0935609T3 (en)
ES (2) ES2175462T3 (en)
HK (2) HK1038573A1 (en)
IL (1) IL128826A0 (en)
PT (2) PT935609E (en)
WO (1) WO1998011134A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
CA2359971A1 (en) 1999-01-08 2000-07-13 Bristol-Myers Squibb Company Modified forms of hepatitis c virus ns3 protease
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
EP1222459A4 (en) 1999-10-14 2003-01-22 Bristol Myers Squibb Co Crystallographic structure of the androgen receptor ligand binding domain
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
CA2429179A1 (en) 2000-11-14 2002-06-23 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells lsi-01
AU2002303218A1 (en) 2001-04-03 2002-11-11 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
WO2005000308A2 (en) * 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
UY28500A1 (en) 2003-09-05 2005-04-29 Vertex Pharma INHIBITORS OF SERINE PROTEASES, IN PARTICULAR PROTEASA NS3-NS4A HCV.
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
CN1894276B (en) 2003-10-27 2010-06-16 威特克斯医药股份有限公司 HCV NS3-NS4A protease resistance mutants
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392590A3 (en) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
MX2008011868A (en) * 2006-03-16 2008-12-15 Vertex Pharma Deuterated hepatitis c protease inhibitors.
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
EP2463285A1 (en) 2007-02-27 2012-06-13 Vertex Pharmaceuticals Inc. Co-crystals and pharmaceutical compositions comprising the same
CA2679426A1 (en) 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
MX2010002407A (en) 2007-08-30 2010-03-26 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same.
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
US9261100B2 (en) 2010-08-13 2016-02-16 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (en) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.

Also Published As

Publication number Publication date
DE69712085T2 (en) 2002-11-28
US6303287B1 (en) 2001-10-16
ATE244729T1 (en) 2003-07-15
PT1118619E (en) 2003-11-28
AU736857B2 (en) 2001-08-02
ATE216400T1 (en) 2002-05-15
IL128826A0 (en) 2000-01-31
ES2202228T3 (en) 2004-04-01
DE69723485D1 (en) 2003-08-14
ATE346088T1 (en) 2006-12-15
AU4414597A (en) 1998-04-02
HK1022700A1 (en) 2000-08-18
ES2175462T3 (en) 2002-11-16
WO1998011134A1 (en) 1998-03-19
PT935609E (en) 2002-09-30
EP0935609B1 (en) 2002-04-17
DE69712085D1 (en) 2002-05-23
EP0935609A1 (en) 1999-08-18
DE69736995T2 (en) 2007-09-20
US6153579A (en) 2000-11-28
CA2264964A1 (en) 1998-03-19
JP2001501602A (en) 2001-02-06
DK0935609T3 (en) 2002-07-22
HK1038573A1 (en) 2002-03-22
DE69723485T2 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
DE69736995D1 (en) Crystallizable compositions containing a complex of hepatitis C virus protease domain NS3 and NS4A and crystals provided therewith
ATE212037T1 (en) INHIBITORS OF SERINE PROTEASES, IN PARTICULAR THE NS3 PROTEASE OF THE HEPATITIS C VIRUS
DE69934104D1 (en) INHIBITORS OF SERIN PROTEASES, ESPECIALLY OF HEPATITIS C VIRUS NS3 PROTEASE
ITRM940092A0 (en) METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLYTIC ACTIVITY OF THE NS3 PROTEASE OF THE HCV VIRUS.
ATE500323T1 (en) SUBTILISIN VARIANT
DE59410380D1 (en) ENDOSOMOLYTICALLY EFFECTIVE PARTICLES
ATE551423T1 (en) SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USES AS THERAPEUTICS AND DIAGNOSTICS
PL331082A1 (en) Method of changing hair growth rate and hair pigmentation by apoptosis induced in hair papillas and composition therefor
DK0754704T3 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
DE60228436D1 (en) USE OF CASTANOSPERMINE DERIVATIVES IN THE TREATMENT OF HEPATITIS C
ATE195124T1 (en) CONDENSED PYRROLO(2,3-C) CARBAZOLE-6-ONE WHICH POTENTIATE THE ACTIVITY OF GAMMA INTERFERON
TR199900903T2 (en) Protein related to a whole family of necrosis factors
DE68927379D1 (en) SLIDE BLOCKING PEPTIDES
HUP9900506A2 (en) Prothrombin derivatives
DE50108409D1 (en) TREATMENT OF SURFACES FOR THE TEMPORARY IMPROVEMENT OF DIRT-RELATED BEHAVIOR
DE69928064D1 (en) MIMOTOPES OF THE HYPERVARIABLE REGION OF THE E2 GLYCOPROTEIN OF HCV AND ITS USES
DE69131253D1 (en) USEFUL VEGETABLE PROTEIN FOR TREATING TUMORS AND HIV INFECTIONS
DE69229119D1 (en) Detergent with enzymes from Verticillium
FI923020A (en) INTE A INTE B-SEQUENCER.
NO20015398L (en) Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines
BR0108187A (en) Trade molecules and related uses
ES2037603A1 (en) Preparations containing protease-tannin complex
SE9604439D0 (en) New receptor
IT1270941B (en) HCV PEPTIDES AND THEIR USES.
심헌섭 Philosophy of Law, Politics, and Society Philosophie des Rechts, der Politick und der Gesellschaft

Legal Events

Date Code Title Description
8364 No opposition during term of opposition